Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 212,357 shares, an increase of 71.6% from the August 15th total of 123,737 shares. Based on an average daily trading volume, of 1,455,508 shares, the short-interest ratio is presently 0.1 days. Approximately 0.2% of the company’s stock are short sold.

Analyst Ratings Changes

A number of research firms recently commented on INDP. Wall Street Zen raised shares of Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Indaptus Therapeutics Price Performance

NASDAQ INDP traded down $0.43 during trading on Wednesday, hitting $3.21. The company’s stock had a trading volume of 1,187,470 shares, compared to its average volume of 624,465. Indaptus Therapeutics has a fifty-two week low of $0.92 and a fifty-two week high of $8.57. The company has a market cap of $427.70 million, a PE ratio of -0.51 and a beta of 1.17. The business’s 50 day simple moving average is $1.77 and its 200-day simple moving average is $2.15.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.57) by $1.55.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.